

Amendments to the Claims under 37 C.F.R. § 1.121

Claim 1 (currently amended): A trimeric polypeptide comprising three monomers, wherein a first portion of each monomer ~~comprises a specifically binds a trimeric cytokine-binding domain~~ and a second portion of each monomer ~~is a tetranectin trimerising-domain structural element~~.

Claims 2-17 (cancelled).

Claim 18 (currently amended): The trimeric polypeptide according to claim 1, wherein the tetranectin trimerising ~~domain~~ structural element comprises an amino acid sequence having at least 87% identity with the amino acid sequence of SEQ ID NO:81.

Claim 19 (currently amended): The trimeric polypeptide according to claim 1, wherein the tetranectin trimerising ~~domain~~ structural element comprises an amino acid sequence having at least 92% identity with the amino acid sequence of SEQ ID NO:81.

Claim 20 (currently amended): The trimeric polypeptide according to claim 1, wherein the tetranectin trimerising ~~domain~~ structural element comprises the amino acid sequence of SEQ ID NO:81.

Claim 21 (currently amended): The trimeric polypeptide according to claim 1, wherein at least one monomer comprises the amino acid sequence of SEQ ID NO:106, SEQ ID NO:108, or SEQ ID NO:107.

Claim 22 (currently amended): The trimeric polypeptide according to claim 1, further comprising a linker between the portion of each monomer that specifically binds a trimeric cytokine binding-domain and the tetranectin trimerising ~~domain~~ structural element.

Claim 23 (previously presented): A pharmaceutical composition comprising the trimeric polypeptide according to claim 1.